Clearmind Medicine Common Shares (NASDAQ: CMND) — Perfil da empresa, notícias e dados financeiros
Clearmind Medicine is a biotech focused on developing psychedelic-based therapies for mental health and substance use disorders.
Clearmind Medicine Common Shares
Clearmind Medicine (NASDAQ:CMND) is a biotech company focused on discovering and developing novel treatments for mental health and substance use disorders. Their operations revolve around pioneering psychedelic-based therapies, aiming to address the significant unmet needs in the mental health care sector. With an innovative approach, their projects include developing CMND-100, a potential treatment for alcohol use disorder, alongside exploring other compounds for various psychological conditions. Their objective is to revolutionize the therapeutic landscape by providing safer, more effective alternatives to current treatments, ultimately improving patient outcomes and well-being. Clearmind is committed to pushing the boundaries of psychiatric care, advancing research, and opening new pathways for those struggling with mental health issues.
Resumo
Operações
Produtos e/ou serviços de Clearmind Medicine Common Shares
- Development of CMND-100, a novel psychedelic compound aimed at treating alcohol use disorder.
- Research into novel therapy-assisted models to improve mental health treatment outcomes.
- Exploration of psychedelic-based treatments for addressing major depressive disorder.
- Innovation in non-invasive technologies for delivering mental health therapies.
- Partnerships for clinical trials to expand understanding of psychedelic compounds' efficacy.
- Outreach programs designed to educate the public and healthcare providers about the potential benefits of psychedelics in mental health treatment.
equipe executiva do Clearmind Medicine Common Shares
- Adi Zuloff-ShaniChief Executive Officer
- Alan Mark RootenbergChief Financial Officer
- Mark HadenVice President of Business Development
- Mylene TouboulAccounting Manager
- Mary-Elizabeth GiffordChief of Global Impact
- Adi VaronController
Últimas notícias sobre a Clearmind Medicine Common Shares
Clearmind presents MEAI data at FDA forum
United StatesClearmind begins CMND-100 AUD trial dosing
United StatesClearmind buys 51% Charging Robotics stake
United StatesClearmind shares CMND-100 trial insights
United StatesClearmind reports MEAI intranasal study progress
United StatesClearmind Medicine finishes dosing 24 trial participants
United States
Comunicados recentes
O que a Clearmind Medicine Common Shares (CMND) comunicou ao mercado, do mais recente para o mais antigo.
- NEWS_HALT halt | CMNDFato relevante
Principais indicadores financeiros
Resultados divulgados pela Clearmind Medicine Common Shares, em USD.
- Cap. de mercado
- 3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -461.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -5,7 mi | -3,9 mi | |
| 0 | -5,7 mi | -5,3 mi | |
| 0 | -6,3 mi | -8,6 mi | |
| 0 | -9 mi | -9,9 mi |